Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Loxapine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Loxapine Succinate Capsules 25 mg |
| 2 | ACTIVE_COMPARATOR | Loxitane® Capsules 25 mg |
| Name | Type | Description |
|---|---|---|
| Loxapine Succinate Capsules 25 mg | DRUG | 25mg, single dose fasting |
| Loxitane® Capsules 25 mg | DRUG | 25mg, single dose fasting |
Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and non-pregnant, non-lactating female a. Women of childbearing potential must have negative serum (Beta HCG) pregnancy tests performed within 14 days prior to the start of the study and on the evening prior to each dose administration. A...
Loxapine is a small molecule drug developed by Viatris Inc. (ticker: VTRS). It is also known as Loxapine Succinate Capsules 25 mg. The drug is currently in Phase 1 clinical development, and its specific indications are undisclosed.
Loxapine targets dopamine receptors DRD2, DRD3, and DRD4, as well as serotonin receptors HTR2A and HTR2C. It acts as an antagonist at these targets, meaning it blocks their activity. This receptor binding profile is characteristic of its small molecule modality.
Loxapine is developed by Viatris Inc., which trades under the ticker symbol VTRS. The company is responsible for the clinical development of Loxapine Succinate Capsules 25 mg.
Loxapine is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The development program includes one completed Phase 1 trial, and there are currently no active trials.
Loxapine has been studied in one completed Phase 1 trial, NCT00648778, titled "Fasting Study of Loxapine Succinate Capsules 25 mg and Loxitane® Capsules 25 mg." The trial enrolled 53 healthy volunteers in the United States and was active-controlled and randomized.